Immunonutrition q modulate the immune system q facilitate

  • Slides: 119
Download presentation

Immunonutrition: q modulate the immune system q facilitate wound healing q reduce oxidative stress

Immunonutrition: q modulate the immune system q facilitate wound healing q reduce oxidative stress

contain certain compounds: q q l-glutamine l-arginine omega-3 fatty antioxidants

contain certain compounds: q q l-glutamine l-arginine omega-3 fatty antioxidants

ASPEN/ESPEN: Immune-modulating enteral formulations (supplemented with agents such as arginine, glutamine, nucleic acid, ω-3

ASPEN/ESPEN: Immune-modulating enteral formulations (supplemented with agents such as arginine, glutamine, nucleic acid, ω-3 fatty acids, and antioxidants) should be used for the appropriate patient population (major elective surgery, trauma, burns, head and neck cancer, and critically ill patients on mechanical ventilation), with caution in patients with severe

To receive optimal therapeutic benefit from the immune-modulating formulations, at least 50%– 65% of

To receive optimal therapeutic benefit from the immune-modulating formulations, at least 50%– 65% of goal energy requirements should be delivered daily.

L-ARGININE q plays fundamental roles in protein metabolism q polyamine synthesis q critical substrate

L-ARGININE q plays fundamental roles in protein metabolism q polyamine synthesis q critical substrate for nitricoxide (NO) production

stimulates the release ; q growth hormone q insulin growth factor and insulin q

stimulates the release ; q growth hormone q insulin growth factor and insulin q all of which may stimulate protein synthesis and promote wound healing. The enzyme, l-arginase, metabolizes l-arginine to l-ornithine, an amino acid implicated in wound healing.

Guidelines for arginine supplementation can be summarized as follows: q. Normal l-arginine intake is

Guidelines for arginine supplementation can be summarized as follows: q. Normal l-arginine intake is 3 to 5 g/d. q. Higher than normal (supraphysiologic) l-arginin supplementation is necessary

q. Dietary supplementation with l-arginine alone should not be used, as only diets q.

q. Dietary supplementation with l-arginine alone should not be used, as only diets q. Immunonutrition incorporating supraphysiologic quantities Of l-arginine ideally should be started preoperatively as an oral dietary supplement and continued in the postoperative

q A clear benefit of l-arginine-containing immunonutrition has not been observed in medical patients,

q A clear benefit of l-arginine-containing immunonutrition has not been observed in medical patients, particularly those with sepsis. q All elective surgical patient populations, including patie undergoing operations for head and neck cancer and patients undergoing cardiac or GI surgery, appear to benefit from the useof immunonutrition formulas containing l-arginine.

Risk vs Benefit Arginine

Risk vs Benefit Arginine

OMEGA-3 FATTY ACIDS qincorporated into phospholipids and thereby influe the structure and function of

OMEGA-3 FATTY ACIDS qincorporated into phospholipids and thereby influe the structure and function of cellular membranes qas substrates for the enzymes cyclooxygenase, lipoxygenase, and cytochrome P 450 qincreasing the quantity of omega-3 fatty acids oxidase (found in fish oils) in the diet reduces platelet aggregation, slows blood clotting, and limits the production of proinflammatory cytokines.

qadministration of dietary lipids rich in omega-3 fatty acids can modify the lipid profile

qadministration of dietary lipids rich in omega-3 fatty acids can modify the lipid profile and favorably affect clinical outcome a mong critically ill patients with ARDS

L-GLUTAMINE: q. The amino acid, l-glutamine, plays a central role in nitrogen transport within

L-GLUTAMINE: q. The amino acid, l-glutamine, plays a central role in nitrogen transport within the body. qused as a fuel by rapidly dividing cells, particular lymphocytes and gut epithelial cells. qsubstrate for synthesis of the important endogenous antioxidant qtranslocation of enteric bacteria and endotoxins is reduced and infective complications less

l-Glutamine unfortunately is unstable in aqueous solutions. To overcome this problem, l-glutamine is added

l-Glutamine unfortunately is unstable in aqueous solutions. To overcome this problem, l-glutamine is added to TPN solutions as adipeptide (l-alanyl-l-glutamine). In patients receiving EN, l-glutamine powder can be dissolved into the nutrition formulation.

Glutamine (enteral): All: The addition of enteral glutamine to an EN regimen (not already

Glutamine (enteral): All: The addition of enteral glutamine to an EN regimen (not already containing supplemental glutamine) should be considered in thermally injured, trauma, and mixed ICU patients.

Selenium; is an essential component of the most important extra- and intra-cellular antioxidant enzyme

Selenium; is an essential component of the most important extra- and intra-cellular antioxidant enzyme family, the glutathione peroxidases (GPX). doses of 750– 1000 mcg/day should probably not be exceeded in the critically ill, and aministration of supraphysiologica ddoses should perhaps be administratlimited to 2 weeks. 20 -60 mcg

Recommended Daily Intake Ascorbic acid (C) 200 mg Vitamin A 3300 IU Vitamin D

Recommended Daily Intake Ascorbic acid (C) 200 mg Vitamin A 3300 IU Vitamin D 5 mg Vitamin E 10 IU

Which Nutrient for Which Population? Elective Surgery Critically Ill General Septic Trauma Burns Acute

Which Nutrient for Which Population? Elective Surgery Critically Ill General Septic Trauma Burns Acute Lung Injury Arginine Benefit No benefit Harm(? ) (Possible benefit) No benefit Glutamine Possible Benefit PN Beneficial Recommend … EN Possibly Beneficial: Consider … Omega 3 FFA … … … Recommend Antioxidants … Consider … … Canadian Clinical Practice Guidelines

ADULT : NUTRITIONAL REQUIREMENTS The nutritional requirements of each patient will depend upon a

ADULT : NUTRITIONAL REQUIREMENTS The nutritional requirements of each patient will depend upon a number of factors including: Age Activity level Current nutritional status Current metabolic and disease states

1)Calorie Requirements: v Metabolic cart vpredictive equations

1)Calorie Requirements: v Metabolic cart vpredictive equations

v If available, indirect calorimetry can be used to measure energy expenditure using gas

v If available, indirect calorimetry can be used to measure energy expenditure using gas exchange v When indirect calorimetry is not possible, there are many possible predictive equations v whichever method (indirect calorimetry or predictive equation) is used, the optimal energy provision for hospitalized patients has yet to be

Metabolic cart (28, 29): Indirect calorimetry using a “metabolic cart” measures actual energy expenditure

Metabolic cart (28, 29): Indirect calorimetry using a “metabolic cart” measures actual energy expenditure by collecting, measuring and analyzing the oxygen consumed (VO 2) and the carbon dioxide (VCO 2) expired. From these measurements the respiratory quotient (RQ) is calculated

a. RQ = VOz/VCOz b. REE = (3. 94 [VOz] + 1. 1 [VCOz])

a. RQ = VOz/VCOz b. REE = (3. 94 [VOz] + 1. 1 [VCOz]) 1. 44 - (2. 17 [UUN])

Note: Patient has to be intubated for the test to be performed FIO 2<60%,

Note: Patient has to be intubated for the test to be performed FIO 2<60%, no air leak chest tube leak.

v PREDICTIVE EQUATIONS v Harris-Benedict v Miflin St. Jeor (MSJ)

v PREDICTIVE EQUATIONS v Harris-Benedict v Miflin St. Jeor (MSJ)

v Use of Indirect Calorimetry vs. Predictive Equations PCG: 2013 Recommendation: There are insufficient

v Use of Indirect Calorimetry vs. Predictive Equations PCG: 2013 Recommendation: There are insufficient data to make a recommendation on the use of indirect calorimetry vs. predictive equations for determining energy needs for nutrition or to guide when nutrition is to be supplemented in critically ill patients.

Conclusions: The use of indirect calorimetry compared to predictive equations to meet enteral nutrition

Conclusions: The use of indirect calorimetry compared to predictive equations to meet enteral nutrition needs has no effect on mortality.

(A. S. P. E. N) v Predictive equations should be used with caution, as

(A. S. P. E. N) v Predictive equations should be used with caution, as they provide a less accurate measure of energy requirements than indirect calorimetry in the individual patient.

Calorie Requirements: CALORIE REQUIREMENTS IN MOST HOSPITALIZED PATIENTS

Calorie Requirements: CALORIE REQUIREMENTS IN MOST HOSPITALIZED PATIENTS

Ø Resting energy expenditure (REE) —the energy expenditure while resting in the supine position

Ø Resting energy expenditure (REE) —the energy expenditure while resting in the supine position with eyes open Ø About 10% greater than BEE

Ø Sleeping energy expenditure (SEE) It is usually 10% to 15% lower than REE

Ø Sleeping energy expenditure (SEE) It is usually 10% to 15% lower than REE Ø Activity energy expenditure (AEE) During maximum exercise it can be 6 - to 10 -fold greater than the BEE.

Ø Total energy expenditure (TEE) the sum of energy expended during periods of sleep,

Ø Total energy expenditure (TEE) the sum of energy expended during periods of sleep, resting, and activity.

estimated resting energy e. REE = e. BEE • stress factor expenditure; estimated total

estimated resting energy e. REE = e. BEE • stress factor expenditure; estimated total energye. TEE = e. REE • activity factor expenditure

v Stress Factors Major surgery: 15%-25% Infection: 20% Long bone fracture: 20%-35% Malnutrition: Subtract

v Stress Factors Major surgery: 15%-25% Infection: 20% Long bone fracture: 20%-35% Malnutrition: Subtract 10%-15% Burns: Up to 120% depending on ex Sepsis: 30%-55% Major trauma: 20%-35% COPD: 10%-15% Sedated mechanically ventilated patients: Subtract 10%-15%.

v Activity Factors Sedated mechanically ventilated patients: 0 -5% Bedridden, spontaneously breathing nonsedated patients:

v Activity Factors Sedated mechanically ventilated patients: 0 -5% Bedridden, spontaneously breathing nonsedated patients: 10%-15% Sitting in chair: 15%-20% Ambulating patients: 20%-25%

Daily Caloric Requirements Using Measured or Estimated REE Sedated mechanically ventilated patients 1. 0

Daily Caloric Requirements Using Measured or Estimated REE Sedated mechanically ventilated patients 1. 0 -1. 2 • REE Unsedated mechanically ventilated patients 1. 2 • REE Spontaneously breathing critically ill 1. 2 -1. 3 • REE patients Spontaneously breathing ward patients (maintenance) Spontaneously breathing ward 1. 3 • REE Using Body Weight 20 -24 kcal/kg 22 -24 kcal/kg 24 -26 kcal/kg

University of Kentucky Medical Center v KCAL/Kg v HBE or MSJ x Injury factor

University of Kentucky Medical Center v KCAL/Kg v HBE or MSJ x Injury factor

University of Kentucky Medical Center q KCAL/Kg v Wound Healing: 30 -35 kcal/kg, increase

University of Kentucky Medical Center q KCAL/Kg v Wound Healing: 30 -35 kcal/kg, increase to 35 -40 kcal/kg if the pt is underweight or losing weight. v Sepsis and Infection: 30 -40 kcal/kg v Trauma: 25 -30 kcal/kg v Acute Spinal Cord Injury (SCI) 23 kcal/kg or HBE w/o stress factor v Chronic SCI: 20 -23 kcal/kg depending on activity v Stroke: 19 -20 kcal/kg or (HBE x. 95 -1. 15) v COPD: 25 -30 kcal/kg

v ARF: 25 -35 kcal/kg v Hepatitis: 25 -35 kcal/kg if wellnourished 30 kcal/kg),

v ARF: 25 -35 kcal/kg v Hepatitis: 25 -35 kcal/kg if wellnourished 30 kcal/kg), 30 -40 kcal/kg if malnourished v Cirrhosis without encephalopathy: 2535 kcal/kg v Cirrhosis with encephalopathy: 35 kcal/kg

v Organ Transplant: 30 -35 kcal/kg v Cancer: Sedentary/normal wt = 25 -30 kcal.

v Organ Transplant: 30 -35 kcal/kg v Cancer: Sedentary/normal wt = 25 -30 kcal. Hypermetabolic, need to gain weight, or anabolic = 30 -35 kcal/kg. v Hypermetabolic, malabsorption, severe stress: > 35 kcal/kg v. Obese = 21 -25 kcal/kg

Estimated Calorie Needs: HBE or MSJ x Injury factor Major Elective HBE x 1.

Estimated Calorie Needs: HBE or MSJ x Injury factor Major Elective HBE x 1. 2 - 1. 3 Major Non-elective HBE x 1. 3 - 1. 5 Minor Elective HBE x 1. 2 Minor Non-elective HBE x 1. 2 - 1. 3 Infection w/temp HBE x 1. 2 - 1. 3

v Traumatic Brain Injury (CHI) HBE x 1. 4 v Multiple trauma & CHI

v Traumatic Brain Injury (CHI) HBE x 1. 4 v Multiple trauma & CHI HBE x 1. 4 – 1. 6 v Pentobarbital coma HBE x 1. 0 – 1. 2 v Stroke and SAH HBE x 1. 0 - 1. 2 v Pneumonia (or ARDS) HBE x 1. 2 - 1. 3 v Neuromuscular Blockade HBE x 1

Energy: ASPEN v Use 25 -30 kcal/kg, or predictive equations, or indirect calorimetry. v

Energy: ASPEN v Use 25 -30 kcal/kg, or predictive equations, or indirect calorimetry. v Consider hypocaloric feeding in critically ill obese (BMI >30 kg/m 2), e. g. 60 -70% of target energy requirements, or 11 -14 kcal/kg actual body weight, or 22 -25 kcal/kg ideal

ESPEN : v 20 -25 kcal/kg in acute phase of critical illness. v 25

ESPEN : v 20 -25 kcal/kg in acute phase of critical illness. v 25 -30 kcal/kg in recovery phase.

Carbohydrates v provide 4 kcal/g (IV dextrose = 3. 4 kcal/g) with an RQ

Carbohydrates v provide 4 kcal/g (IV dextrose = 3. 4 kcal/g) with an RQ of 1. 0. v Between 40% and 60% of total caloric needs (or 70% of nonprotein calories)

Minimum 2 g/kg ESPEN 2009 Maximal glucose oxidation rate is 4 -7 mg/kg/minute/24 hours.

Minimum 2 g/kg ESPEN 2009 Maximal glucose oxidation rate is 4 -7 mg/kg/minute/24 hours. Ideally keep to ≤ 5 mg/kg/minute/24 hours

Protein 1. Normal patient = 0. 8 to 1. 0 g/kg 2. Postsurgical, mild

Protein 1. Normal patient = 0. 8 to 1. 0 g/kg 2. Postsurgical, mild trauma = 1. 25 to 1. 5 g/kg 3. Severe trauma, sepsis, organ failure = 1. 5 to 2. 0 4. Burn (>20%) or severe head injury ~2. 0 g/kg

1. 3 -1. 5 g protein/kg. ESPEN 1. 2 -2. 0 g protein/kg if

1. 3 -1. 5 g protein/kg. ESPEN 1. 2 -2. 0 g protein/kg if BMI<30 kg/m 2. ASPEN 2 g/kg ideal weight if BMI 30 -40 kg/m 2. 5 g/kg ideal weight if BMI >40 kg/m 2.

Fat v provides 9 kcal/g with an RQ of 0. 7. v Between 20%

Fat v provides 9 kcal/g with an RQ of 0. 7. v Between 20% and 30% of total caloric requirements (or 30% of nonprotein calories) 0. 7 -1. 5 g/kg. ESPEN

ENTERAL NUTRITION

ENTERAL NUTRITION

INDICATIONS FOR INITIATION OF ENTERAL NUTRIT 1)Oral intake is contraindicated Examples Dysphagia, mechanical ventilation,

INDICATIONS FOR INITIATION OF ENTERAL NUTRIT 1)Oral intake is contraindicated Examples Dysphagia, mechanical ventilation, mandibular fractures, head & neck surgery, neurological impairment, demyelinating diseases such as amyotrophic lateral sclerosis, muscular dystrophy, etc.

2)Inability to meet markedly increased nutritional needs with oral intake Examples Burns, trauma, radiation

2)Inability to meet markedly increased nutritional needs with oral intake Examples Burns, trauma, radiation therapy, chemotherapy, sepsis/infection, closed head injury

3)Inability to meet basic nutritional needs with oral intake alone Examples Anorexia, cancer, head

3)Inability to meet basic nutritional needs with oral intake alone Examples Anorexia, cancer, head and neck tumors

4)Need to bypass part of the GI tract to allow enteral nutrition Examples Pancreatitis,

4)Need to bypass part of the GI tract to allow enteral nutrition Examples Pancreatitis, gastric outlet obstruction, esophageal cancer, gastroparesis

5)The need for supplemental nutrition due to decreased absorption Examples Short bowel syndrome, inflammatory

5)The need for supplemental nutrition due to decreased absorption Examples Short bowel syndrome, inflammatory bowel disease, fat malabsorption or other malabsorptive syndromes such as cystic fibrosis

Benefits of Enteral Nutrition (compared with Parenteral Nutrition) Stimulates immune barrier function Physiologic presentation

Benefits of Enteral Nutrition (compared with Parenteral Nutrition) Stimulates immune barrier function Physiologic presentation of nutrients Maintains gut mucosa Attenuates hypermetabolic response Simplifies fluid/electrolyte management More “complete” nutrition than parenteral nutrition o iron, fiber, glutamine, etc. are not provided. Less infectious complications (and costs associated with these complications) Stimulates return of bowel function Less expensive

Delivery Method: Continuous or cyclic: Intermittent feeding Bolus feeding

Delivery Method: Continuous or cyclic: Intermittent feeding Bolus feeding

Continuous or cyclic 18 -24 h 25 cc/h 8 -24 h double 125 -150

Continuous or cyclic 18 -24 h 25 cc/h 8 -24 h double 125 -150 cc/h

Intermittent feeding usually 240 -480 ml, over a 45 -60 minute period 5 -8

Intermittent feeding usually 240 -480 ml, over a 45 -60 minute period 5 -8 times per day. Preferred by ambulatory patients. Disadvantage includes: poor tolerance since a larger feeding volume is administered

Bolus feeding is discouraged in the I rapid infusion via syringe through a gastrostomy

Bolus feeding is discouraged in the I rapid infusion via syringe through a gastrostomy tube may result in nausea, diarrhea, distention, cramps, or aspiration 300 -500 cc 3 -5 h 5 -10 min

Carbohydrate (CHO): Ø Concentration & form of CHO constitute major differences between vformulas Forms

Carbohydrate (CHO): Ø Concentration & form of CHO constitute major differences between vformulas Forms of CHO include: ü Simple sugars and monosaccharides (glucose and fructose). ü Disaccharides (sucrose, lactose, and maltose) require enzymatic conversion to monosaccharides in the intestinalbrush border prior to

ü Polysaccharides and oligosaccharides , produced from hydrolysis of starch, result in glucose polymers

ü Polysaccharides and oligosaccharides , produced from hydrolysis of starch, result in glucose polymers of intermediate chain lengths. Starch hydrolysis increases the solubility and osmolality of the product

Protein: v Three major categories are classified by degree of digestion required: Ø Intact

Protein: v Three major categories are classified by degree of digestion required: Ø Intact protein, found in whole foods, requires complete digestion. Ø Crystalline amino acids – theoretically require minimal digestion. The small particle size increases the osmolality

Ø Hydrolyzed protein –enzymatically hydrolyzed to smaller peptide fragments and free amino acids, partially

Ø Hydrolyzed protein –enzymatically hydrolyzed to smaller peptide fragments and free amino acids, partially hydrolyzed protein requires digestion while di and tri-peptides are absorbed directly. Useful in conditions such as: short bowel and Crohn's disease and pancreatic insufficiency.

Fat: Ø Increases the caloric density but does not contribute to the osmolality. Ø

Fat: Ø Increases the caloric density but does not contribute to the osmolality. Ø Most formulas contain long chain triglycerides (LCT) with variable amounts of medium-chain triglycerides (MCT) and mono and diglycerides.

 MCT are transported via the portal system directly into the blood stream they

MCT are transported via the portal system directly into the blood stream they are oxidized to ketones and carbon dioxide. MCT does not require emulsification for absorption their use is indicated with CF, liver disease, pancreatitis, and other disorders where fat absorption may be impaired.

Timing of enteral nutrition v All: EN should be started within the first 24–

Timing of enteral nutrition v All: EN should be started within the first 24– 48 hours following admission

PCG 2013 Recommendation: Based on 16 studies, we recommend early enteral nutrition (within 24

PCG 2013 Recommendation: Based on 16 studies, we recommend early enteral nutrition (within 24 -48 hours following admission to ICU) in critically ill patients.

Conclusions: 1) Early enteral nutrition, when compared to delayed nutrient intake is associated with

Conclusions: 1) Early enteral nutrition, when compared to delayed nutrient intake is associated with a trend towards a reduction in mortality in critically ill patients. 2) Early enteral nutrition, when compared to delayed nutrient intake is associated with a significant reduction in infectious complications

3) Early enteral nutrition, when compared to delayed nutrient intake has no effect on

3) Early enteral nutrition, when compared to delayed nutrient intake has no effect on ICU or hospital length of stay. 4) Early enteral nutrition, when compared to delayed nutrient intake improves nutritional intake

 Achieving Target Dose of Enteral Nutrition PCG v There were no new randomized

Achieving Target Dose of Enteral Nutrition PCG v There were no new randomized controlled trials since the 2009 update and hence there are no changes to the following summary of evidence.

Dosage of enteral feeding v ASPEN: The feedings should be advanced toward the patient’s

Dosage of enteral feeding v ASPEN: The feedings should be advanced toward the patient’s goal over the next 48– 72 hours v Efforts to provide > 50%– 65% of goal energy should be made in order to achieve the clinical benefit of EN over the first week of hospitalisation.

v. ESPEN: No general amount can be recommended as EN therapy has to be

v. ESPEN: No general amount can be recommended as EN therapy has to be adjusted according to the progression/course of the disease and to gut tolerance

v ASPEN/CCPG: If unable to meet energy requirements (100% of target goal energy) after

v ASPEN/CCPG: If unable to meet energy requirements (100% of target goal energy) after 7– 10 days by the enteral route alone, consider initiating supplemental parenteral nutrition v ESPEN: All patients who do not meet their nutritional needs after 2 days should receive supplemental PN.

Haemodynamically unstable patien ASPEN: In the setting of haemodynamic compromise : patients requiring significant

Haemodynamically unstable patien ASPEN: In the setting of haemodynamic compromise : patients requiring significant haemodynamic support including high dose catecholamine agents, alone in combination with large volume fluid or blood product resuscitation to maintain cellular perfusion), EN should be withheld until the patient is fully resuscitated and/or stable.

Immune-modulating enteral formulation ASPEN/ESPEN: Immune-modulating enteral formulations supplementaed with agents such s arginine, glutamine,

Immune-modulating enteral formulation ASPEN/ESPEN: Immune-modulating enteral formulations supplementaed with agents such s arginine, glutamine, nucleic acid, ω-3 fatty acids, and antioxidants) should be used for the appropriate patient population (major elective surgery, trauma, burns, head and neck cancer, and critically ill patients on mechanical ventilation), with caution in patients with severe sepsis

Complications of overfeeding include (but not limited to): . Hyperglycemia . Lipogenesis Fluid and

Complications of overfeeding include (but not limited to): . Hyperglycemia . Lipogenesis Fluid and fat gain rather than lean body mass gain Fatty liver Immunosuppression (with excessive lipid and linoleic acid intake) Increased minute ventilation (VE) Excessive CO 2 production impairing pulmonary

q DRUG NUTRIENT INTERACTIONS WITH ENTERAL PRODUCTS Only administer sucralfate (Carafate. R), omeprazole, antacids,

q DRUG NUTRIENT INTERACTIONS WITH ENTERAL PRODUCTS Only administer sucralfate (Carafate. R), omeprazole, antacids, iron salts, and ketoconazole (Nizoral. R) into the stomach

Stop continuous tube feedings for 1 hour before and 1 hour after each phenytoin

Stop continuous tube feedings for 1 hour before and 1 hour after each phenytoin (Dilantin. R) dose to maximize the drug absorption.

When diarrhea occurs, determine if any medication contains excessive quantities of sorbitol. Examples include:

When diarrhea occurs, determine if any medication contains excessive quantities of sorbitol. Examples include: acetaminophen elixir, codeine solution, diazepam solution, Lomotil. R, furosemide solution, guaifenesin syrup, lithium citrate syrup, metoclopramide syrup, morphine sulfate solution potassium chloride elixirs, and some theophylline solutions.

GENERAL GUIDELINES FOR ADMINISTERING MEDICATIONS WITH ENTERAL FEEDINGS: 1)Stop the tube feeding prior to

GENERAL GUIDELINES FOR ADMINISTERING MEDICATIONS WITH ENTERAL FEEDINGS: 1)Stop the tube feeding prior to administration of meds. 2)Flush the feeding tube with 20 -30 ml of warm water or appropriate volume before and after giving medication through the tube.

3)If more than one medication is being given at the same time, give each

3)If more than one medication is being given at the same time, give each medication separately and flush the tube with 5 -15 ml of warm water between medications. 4)Use liquid preparation if possible (if patient does not have diarrhea).

5)If a tablet form must be used, be sure it is finely crushed and

5)If a tablet form must be used, be sure it is finely crushed and dispersed in warm water. 6)Do not crush enteric-coated, sublingual, or sustained-release tablets, if in doubt check with Pharm. D. 7)tube feeding when done giving medications.

7)Most liquid medications are hypertonic and should be diluted with 30 -60 ml of

7)Most liquid medications are hypertonic and should be diluted with 30 -60 ml of water prior to administration 8)tube feeding when done giving medications.

Categories of Enteral Formulas

Categories of Enteral Formulas

v Return up to 250 ml gastric residuals to the patient. v Notify physician

v Return up to 250 ml gastric residuals to the patient. v Notify physician if feedings held twice in 24 hours.

ASPEN -500 ml Holding EN for gastric residual volumes < 500 m. L in

ASPEN -500 ml Holding EN for gastric residual volumes < 500 m. L in the absence of other signs of intolerance should be avoided.

v For high-risk patients or those shown to be intolerant to gastric feeding, delivery

v For high-risk patients or those shown to be intolerant to gastric feeding, delivery of EN should be switched to continuous infusion. v Agents to promote motility such as prokinetic drugs (metoclopramide and erythromycin) or narcotic antagonists (naloxone and alvimopan) should be initiated where clinically feasible.

v Diverting the level of feeding by postpyloric tube placement should be considered. v

v Diverting the level of feeding by postpyloric tube placement should be considered. v Use of chlorhexidine mouthwash twice a day shou be considered to reduce risk of ventilator-associate pneumonia.

In the ICU setting, evidence of bowel motility (resolution of clinical ileus) is not

In the ICU setting, evidence of bowel motility (resolution of clinical ileus) is not require in order toinitiate EN in the ICU.

Critically ill patients should be fed via an enteral access tube placed in the

Critically ill patients should be fed via an enteral access tube placed in the small bowel if at high risk for aspiration or after showing intoleranceto gastric feeding.

v Parenteral nutrition is usually indicated in the following situations: 1)Documented inability to absorb

v Parenteral nutrition is usually indicated in the following situations: 1)Documented inability to absorb adequate nutrients via the gastrointestinal tract Massive small-bowel resection / Short bowel syndrome (at least initially) Radiation enteritis Severe diarrhea

2)Complete bowel obstruction 3)Severe catabolism with or without malnutrition when gastrointestinal tract is not

2)Complete bowel obstruction 3)Severe catabolism with or without malnutrition when gastrointestinal tract is not usable within 5 -7 days

4)Inability to obtain enteral access 5)Inability to provide sufficient nutrients/fluids enterally 6) Pancreatitis in

4)Inability to obtain enteral access 5)Inability to provide sufficient nutrients/fluids enterally 6) Pancreatitis in the setting of intolerance to jejunal delivery of nutrients 7) Persistent GI hemorrhage 8) Acute abdomen/ileus

9)High output enterocutaneous fistula and EN access cannot be obtained distal to the site.

9)High output enterocutaneous fistula and EN access cannot be obtained distal to the site. 10) Trauma requiring repeat surgical procedures / NPO status

v Parenteral nutrition may be indicated in the following situations: ü Enterocutaneous fistula as

v Parenteral nutrition may be indicated in the following situations: ü Enterocutaneous fistula as above ü Inflammatory bowel disease unresponsive to medical therapy ü Hyperemesis gravidarum when nausea and vomiting persist longer than 5 -7 days and enteral nutrition is not possible ü Partial small bowel obstruction ü Intensive chemotherapy /

v. Contraindications for Parenteral Nutrition: 1)Functioning gastrointestinal tract 2)Treatment anticipated for less than 5

v. Contraindications for Parenteral Nutrition: 1)Functioning gastrointestinal tract 2)Treatment anticipated for less than 5 days in patients without severe malnutrition 3)Inability to obtain venous access 4)A prognosis that does not warrant aggressive nutrition support 5)When the risks of PN are judged to exceed the potential benefits

COMPONENTS OF PARENTERAL NUTRIT A. MACRONUTRIENTS 1)CARBOHYDRATE 2. PROTEIN 3)FAT

COMPONENTS OF PARENTERAL NUTRIT A. MACRONUTRIENTS 1)CARBOHYDRATE 2. PROTEIN 3)FAT

CARBOHYDRAT Dextrose contains 3. 4 kcal/g (CHO E is given as a dextrose monohydrate)

CARBOHYDRAT Dextrose contains 3. 4 kcal/g (CHO E is given as a dextrose monohydrate) Requirements: Minimum: 1 mg/kg/minute 1440 mg/kg/24 hrs Maximum: 5 mg/kg/minute 7200 mg/kg/24 hrs OR 7 g/kg/day OR 24 dextrose kcal/kg/day.

v Consequences of excess CHO administration: Hyperglycemia Glucosuria Synthesis and storage of fat Hepatic

v Consequences of excess CHO administration: Hyperglycemia Glucosuria Synthesis and storage of fat Hepatic steatosis Increased carbon dioxide production impairing pulmonary status/vent wean

Requirements: Approximately 16% of protein or amino acids are nitrogen. The goal should be

Requirements: Approximately 16% of protein or amino acids are nitrogen. The goal should be to provide adequate protein to maintain a positive (2 to 4 g) Requirements range from 0. 8 g/kg/day to 2. 5 g/kg/day. Generally 15 – 20% of the daily caloric intake should come from protein.

PROTEIN v Amino acid = 4 kcal/g v Protein calories should be included when

PROTEIN v Amino acid = 4 kcal/g v Protein calories should be included when calculating total caloric requirements

FAT v Minimum: To prevent essential fatty acid deficiency (EFAD), 2% to 4% of

FAT v Minimum: To prevent essential fatty acid deficiency (EFAD), 2% to 4% of the total caloric requirement should come from linoleic acid (25 to 100 mg/kg/day) v Maximum: Maximal fat dosage should not exceed 60% of calories OR 1. 0 - 2. 5 g/kg/day

v. Lipids should be used with caution in patients with serum triglycerides (TG) >

v. Lipids should be used with caution in patients with serum triglycerides (TG) > 400 mg/dl. v Use with caution in patients allergic to eggs.

v. Lipids are generally administered over a 24 hour period v Guidelines for rate

v. Lipids are generally administered over a 24 hour period v Guidelines for rate of infusion are < 0. 11 g / kg / hr

Consequences of excess lipid administra ü Fat overload syndrome with neurologic, cardiac, pulmonary, hepatic

Consequences of excess lipid administra ü Fat overload syndrome with neurologic, cardiac, pulmonary, hepatic and renal dysfunction ü Thrombocyte adhesiveness ü Accumulation of lipid in the reticuloendothelial system (RES), leading to RES dysfunction

MICRONUTRIENTS:

MICRONUTRIENTS:

PARENTERAL NUTRITION CALCULATIO CUSTOM PN: Step 1 – Determine protein and calorie needs Step

PARENTERAL NUTRITION CALCULATIO CUSTOM PN: Step 1 – Determine protein and calorie needs Step 2 – Subtract protein calories (grams protein x 4) from total calories Step 3 – Subtract lipid calories* from remaining calories Step 4 – remaining will be dextrose calories

Minimum flow rates: Dex/50 + g Pro/215 + 5 = minimum flow rate Central:

Minimum flow rates: Dex/50 + g Pro/215 + 5 = minimum flow rate Central: [(Dextrose kcals X 0. 42) + (grams of protein X 10)] ÷ 24 = minimum hourly flow rate. Add 5 ml/hour for MVI, trace elements, etc. Round up to nearest increment of 5. Peripheral: [(Dextrose kcals x 0. 15) + grams of protein] ÷ 2. 1 = minimum hourly flow rate. Add 5 ml/hour for MVI, trace elements, etc. Round up to nearest increment of 5.

COMPLICATIONS ASSOCIATED WITH PARENTERAL NUTRITION : ü Metabolic complications; hyperglycemia is the most common

COMPLICATIONS ASSOCIATED WITH PARENTERAL NUTRITION : ü Metabolic complications; hyperglycemia is the most common – tight blood glucose control is optimal. ü Gastrointestinal complications: steatohepatitis, cholestasis ü Pharmacological complications ü Manganese toxicity is possible with prolonged use of PN

ü Infection / sepsis ü Metabolic bone disease

ü Infection / sepsis ü Metabolic bone disease

Nutritional modifications in disease A. Diabetes. Low simple sugar. high fiber. and high fat

Nutritional modifications in disease A. Diabetes. Low simple sugar. high fiber. and high fat to minimize hyperglycemia. B. Renal failure. High calorie. low protein. and low electrolytes (phosphorus. potassium) to prevent volume overload. hyperammonemia. and electrolyte imbalance. However, in patients on dialysis. protein requirements may actually increase. C. Liver failure. Low protein. high branch chain amino acids to prevent encephalopathy. D. Respiratory failure. High calorie, high fat (low carbohydrate) to prevent CO 2 accumulation. E. Pancreatitis. Enteral. postpyloric (nasojejunal) feeding is superior to TPN.

Grade 1 ascites Mild ascites only detectable by ultrasound No treatment Grade 2 ascites

Grade 1 ascites Mild ascites only detectable by ultrasound No treatment Grade 2 ascites Moderate ascites evident by moderate symmetrical distension of abdomen Restriction of sodium intake and diuretics Grade 3 ascites Large or gross ascites with marked abdominal distension Large-volume paracentesis followed by restriction of sodium intake and diuretics (unless patients have refractory ascites)